看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。' U( N+ a8 y" w- M* H" D
# E3 ~# ?& @7 {6 [
, |" k& k! c) _0 x6 YCurrently available feasibility data for possible combination strategies. 7 P. l2 t5 k! i
————————————————————————————————
F! p; w' w1 ~& w7 K8 o2 ^6 r1 KCombination Feasibility according to preliminary data - L; O" A# o" f$ W* [5 ]
——————————————————————————————————# d2 E- |+ L7 k1 x
Bevacizumab + sorafenib Yes, reduced dose
8 _' D9 M/ l- _: rBevacizumab + sunitinib† No
) L: w. g1 }+ z& DBevacizumab + temsirolimus Yes
+ r. L9 _" m! `; o; @9 Z0 c% QBevacizumab + everolimus Yes ( t5 O* z) O: x! t
Sorafenib + sunitinib ? 1 m7 N+ [) v* T
Sorafenib + temsirolimus Yes, reduced dose
4 G+ W3 K+ g! G8 I/ u7 `2 [Sorafenib + everolimus Yes, reduced dose
7 ^* P) D |9 I9 ~3 p3 @0 LSunitinib + temsirolimus† No 7 T8 `4 _/ S! K3 G$ l' ?, w4 P
Sunitinib + everolimus ? $ ?. w, \+ V4 X0 T5 a
Temsirolimus + everolimus ? $ w. {# X2 A$ \& o1 |; Q
————————————————————
' P* V) ?' e3 i( d/ ^5 O; `% P†Led to US FDA warning.
) }0 V ~1 O4 s6 o?: As yet unattempted combination.
8 L/ a: @+ @6 `2 G$ l a8 e# { |